Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDS
December 10th 2015Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.
Watch
Dr. Ola Landgren on Three-Drug Treatments and the Use of Monoclonal Antibodies
December 9th 2015Ola Landgren, MD, PhD, on the progression treatments from combinations toward three-drug treatments and the use of monoclonal antibodies. Landgen adds that while he does have faith that monoclonal antibodies will change the treatment landscape in oncology, he says they could very well be combined with old and new drugs.
Watch
Dr. William Wierda on Ibrutinib and Idelalisib as Treatments in NSCLC
December 9th 2015William G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.
Watch
Dr. Barbara Burtness on the Psychology of Talking to Patients About Enrolling in Clinical Trials
December 8th 2015Burtness says on average, medical professionals should take about 4 minutes or longer to properly explain the clinical trial to their patients, as well as leave ample time for questions at the end of the conversation.
Watch
Dr. David Steensma on Midostaurin and its Future Uses in Acute Leukemia
December 8th 2015David Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
Watch
Dr. Farrukh Awan on Clinical Activity of Entospletinib in Patients with CLL
December 7th 2015Farrukh T. Awan, MBBS, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia who were previously treated with a B-cell receptor pathway signaling inhibitor.
Watch
Dr. Stephen Nimer on MSI2 as a Requirement for Maintaining Activated MDS Stem Cells
December 6th 2015Stephen Nimer, MD, leukemia and lymphoma treatment specialist, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses results of a study which examined Musashi2 as a requirement for maintaining activated myelodysplastic syndrome (MDS) cells.
Watch
Dr. John Leonard on Top Lymphoma Studies at the 2015 ASH Annual Meeting
December 6th 2015Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease
Watch
Dr. Robin Jones on Olaratumab and Doxorubicin Combination in Patients with Soft Tissue Sarcoma
December 4th 2015Robin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal antibody olaratumab in combination with doxorubicin in metastatic soft tissue sarcoma.
Watch